Skip to main content

Whatman's Combichip Wins CE Mark Around Nine Months Later Than Expected

NEW YORK, (GenomeWeb News) – Whatman today said that its Combichip multiplex protein biochip has received CE registration as an in vitro diagnostic and will be available to reference labs as a CE-marked IVD kit.
The product, indicated for autoimmune diseases, won the agency’s approval around three months later than its most recent prediction, and around eight months later than it had originally expected it to become approved.
As reported by GenomeWeb News sister publication BioArray News, Whatman in August 2005 said it would launch the Combichip as an IVD by the end of that year. But in January officials pushed back that date to the first quarter of 2006.
In May Whatman filed the Combichip with European regulators and said at the time that it expected to win the CE Mark as early as June.
The Combichip requires a single, low-volume serum sample to generate results for 14 different analytes. It also reduces analysis time to two or three hours, Whatman said.
The assay system, developed in partnership with Privates Institut fur Immunologie und Molekulargenetik, currently identifies antibodies associated with approximately 10 different autoimmune diseases, including systemic and neonatal lupus and systemic sclerosis.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.